期刊文献+

高危骨髓增生异常综合征的治疗和分析

Analysis and treatment of patients with highrisk myelodysplastic syndrome
原文传递
导出
摘要 目的探讨高危骨髓增生异常综合征(MDS)的临床特点和实验研究,观察联合化疗对高危MDS的疗效,对治疗效果进行分析。方法应用联合化疗方案对31例高危MDS患者进行治疗,结合实验室检查结果分析其疗效。结果 31例高危MDS患者,化疗后完全缓解12例(38.7%),该12例患者中位生存期为18个月。19例未缓解者中位生存期为7个月。化疗主要不良反应为骨髓抑制期感染,少数出现肝功能异常和心肌损害。结论联合化疗对高危MDS患者有一定疗效,需加强对症支持治疗。 Objective To study the clinical characteristics and laboratory results of patients with high risk myelodysplastic syndrome(MDS).The curative effects of common chemotherapy on patients were observed.Methods Common chemotherapy was used in 31 cases of high risk MDS,and based on the lab results,the curative effects on the patients were analyzed.Results Among the 31 cases of high risk MDS,after treated with common therapy,12 cases(38.7%) got complete remission(CR).Midian survival time was 18 months of the 12 cases.Midian survival time was 7 months of the 19 NR cases.The main side effects of chemotherapy included infection in bone marrow inhibition period.A few cases had liver funtion abnormality or myocardial damage.Conclusion Common chemotherapy is effective to treat high risk MDS,and symptomatic supportive treatment should be strengthened.
出处 《临床医学》 CAS 2012年第4期6-7,共2页 Clinical Medicine
关键词 骨髓增生异常综合征 临床特征 化疗 Myelodysplastic syndrome Clinical characteristic Chemotherapy
  • 相关文献

参考文献4

二级参考文献14

  • 1肖志坚.重视和加强我国儿童骨髓增生异常综合征的研究[J].中国小儿血液,2005,10(3):97-98. 被引量:6
  • 2肖志坚.骨髓增生异常综合征:现况与问题[J].白血病.淋巴瘤,2005,14(4):193-196. 被引量:31
  • 3List AF. Myelodysplastic syndromes (MDS): an international practice and treatment survey. ASH Annual Meeting Abstracts,Atalanta, 2005:2534.
  • 4Malcovati L, Germing U, Kuendgen A, et al. A WHO Classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. ASH Annual Meeting Abstracts, Atalanta, 2005:788.
  • 5Deeg HJ. Transplant strategies for patients with myelodysplastic syndromes. Curt Opin Hematol, 2006, 13:61-66.
  • 6Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 2004, 104:579-585.
  • 7List AF, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med, 2005,352:549-557.
  • 8Kaminskas E, Farrell A, Abraham S, et al. Approval summary:azacitidine for treatment of myelodysplastic syndrome subtypes.Clin Cancer Res, 2005, 11:3604-3608.
  • 9Wijermans PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine)in 177 patients. Ann Hematol, 2005, 84 Supple 13: 9-17.
  • 10Kantarjian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Results of a phase Ⅲ randomized study. Cancer, 2006, 106 : 1794-1803.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部